Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 27Irinotecan 8Filgrastim 8Carmustine 7Carboplatin 7Surgical Procedures, Operative 6O(6)-benzylguanine 6Flucytosine 6sargramostim 4Vorinostat 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4vocimagene amiretrorepvec 3lonafarnib 3Radiosurgery 3Lenalidomide 3Imatinib Mesylate 3Genetic Therapy 3Erlotinib Hydrochloride 3Cyclophosphamide 3Bortezomib 3temsirolimus 2cediranib 2aldesleukin 2Vincristine 2Vinblastine 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Peripheral Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Oligodendroglioma × paclitaxel-Angiopep-2 conjugate × Clear all
NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡